Figure 5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer

Comparison of cell growth–inhibitory activity and toxicity of ZSTK3744 and other AhR agonists. MM468 (A), MM453 (B), DU4475 (C), and Hs578T cells (D) were treated with ZSTK3744, aminoflavone, or 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F-203) at the indicated concentrations for 72 hours, and cell viability was assessed using the Cell Counting Kit-8 assay (mean ± SD of quadruplicate experiments). E, PCLS were continuously treated with ZSTK3744 (0.01, 0.1, 1, and 10 μmol/L), AFP464 (0.1, 1, and 10 μmol/L), or Phortress (0.1, 1, and 10 μmol/L) for 7 days. Cell viability was measured using the Cell Counting Kit-8 assay (mean ± SD of triplicate experiments). Statistical analysis was performed using one-way ANOVA, followed by a Dunnett test (*, P < 0.01). F,CYP1A1 mRNA levels after treatment with ZSTK3744, AFP464, or Phortress were quantified using qRT-PCR. Data from PCLS experiments were generated at the IIVS. LPS, lipopolysaccharide.